DB
ONCT

Dmitry Balyasny’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Dmitry Balyasny’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-608
Closed -$13K – 3378
2022
Q2 		$13K Buy
+608
New +$13.6K ﹤0.01% 2549

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Dmitry Balyasny's ONCT Position: Q3 2022 in Review

Dmitry Balyasny sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 608 shares — an estimated $13K sold.

Dmitry Balyasny first reported a position in ONCT in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Dmitry Balyasny reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 608 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $13K.
  • Dmitry Balyasny first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Dmitry Balyasny's Oncternal Therapeutics, Inc. Common Stock position peaked at $13K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.